Tyra Biosciences’ (TYRA) “Outperform” Rating Reiterated at Oppenheimer

Oppenheimer restated their outperform rating on shares of Tyra Biosciences (NASDAQ:TYRA) in a research report sent to investors on Wednesday, Benzinga reports. The firm currently has a $28.00 price target on the stock.

Several other equities research analysts have also commented on TYRA. Wedbush reissued an outperform rating and set a $28.00 price objective on shares of Tyra Biosciences in a research note on Wednesday. HC Wainwright reissued a buy rating and issued a $23.00 price target on shares of Tyra Biosciences in a research report on Wednesday.

Tyra Biosciences Stock Performance

Shares of TYRA stock opened at $17.10 on Wednesday. The firm has a market cap of $898.43 million, a P/E ratio of -10.18 and a beta of 1.01. The business’s 50 day moving average price is $17.70 and its 200-day moving average price is $16.61. Tyra Biosciences has a fifty-two week low of $10.38 and a fifty-two week high of $21.14.

Tyra Biosciences (NASDAQ:TYRA) last announced its earnings results on Thursday, May 9th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.11. As a group, equities analysts predict that Tyra Biosciences will post -1.71 EPS for the current year.

Insider Transactions at Tyra Biosciences

In other Tyra Biosciences news, COO Daniel Bensen sold 3,502 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $20.00, for a total transaction of $70,040.00. Following the completion of the sale, the chief operating officer now directly owns 427,981 shares in the company, valued at approximately $8,559,620. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 15.40% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in TYRA. Federated Hermes Inc. grew its position in shares of Tyra Biosciences by 1,244.2% during the fourth quarter. Federated Hermes Inc. now owns 2,070 shares of the company’s stock worth $29,000 after purchasing an additional 1,916 shares in the last quarter. Exchange Traded Concepts LLC raised its position in shares of Tyra Biosciences by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 9,531 shares of the company’s stock valued at $132,000 after buying an additional 2,417 shares during the last quarter. AJOVista LLC purchased a new position in shares of Tyra Biosciences in the fourth quarter worth $59,000. Wellington Management Group LLP lifted its holdings in shares of Tyra Biosciences by 8.8% in the fourth quarter. Wellington Management Group LLP now owns 102,436 shares of the company’s stock worth $1,419,000 after buying an additional 8,324 shares in the last quarter. Finally, Fishman Jay A Ltd. MI bought a new position in shares of Tyra Biosciences during the first quarter worth $246,000. 84.14% of the stock is owned by hedge funds and other institutional investors.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.